APRI Apricus Biosciences, Inc.

3.21
+0.31  (10.94%)
Previous Close 2.89
Open 2.90
Price To book 0.00
Market Cap 24.79M
Shares 7,733,000
Volume 2,421,917
Short Ratio 0.25
Av. Daily Volume 1,299,290

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

NDA resubmission planned for 3Q 2017.
Vitaros
Erectile dysfunction
Phase 2b planned - seeking partnership
RayVa
Secondary Raynaud's Phenomenon

Latest News

  1. APRICUS BIOSCIENCES, INC. Files SEC form 8-K, Other Events
  2. Apricus Biosciences Receives Positive Nasdaq Listing Determination
  3. Apricus Biosciences Receives Positive Nasdaq Listing Determination
  4. Apricus Biosciences to Present at the 19th Annual BIO CEO & Investor Conference
  5. Apricus Biosciences to Present at the 19th Annual BIO CEO & Investor Conference
  6. Thursday’s Top Biopharma Movers
  7. Apricus (APRI) Stock Gains on Vitaros' Approval in Mexico
  8. How Erectile Dysfunction in Mexico Just Made One Micro-Cap Stock More Than Double
  9. Wednesday’s Top Biopharma Winners
  10. Apricus Biosciences Announces Approval of Vitaros® for the Treatment of Erectile Dysfunction in Mexico
  11. Apricus Biosciences Announces Approval of Vitaros® for the Treatment of Erectile Dysfunction in Mexico
  12. Latest Reports on Biocept and Apricus Biosciences as President Trump's Comments Put Pressure on Drug Manufacturers
  13. Apricus Biosciences Promotes Mary Naggs to Vice President, General Counsel
  14. Apricus Biosciences Promotes Mary Naggs to Vice President, General Counsel
  15. Apricus Biosciences Promotes Mary Naggs to Vice President, General Counsel
  16. Apricus Launches Vitaros in Lebanon for Erectile Dysfunction
  17. Apricus Biosciences Announces the Launch of Vitaros® for the Treatment of Erectile Dysfunction in Lebanon by Elis Pharmaceuticals
  18. Apricus Biosciences Announces the Launch of Vitaros® for the Treatment of Erectile Dysfunction in Lebanon by Elis Pharmaceuticals
  19. Apricus Biosciences Announces the Launch of Vitaros® for the Treatment of Erectile Dysfunction in Lebanon by Elis Pharmaceuticals
  20. APRICUS BIOSCIENCES, INC. Files SEC form 8-K, Change in Directors or Principal Officers